Navigation Links
IGI Laboratories, Inc. Announces Twelfth ANDA Submission
Date:9/18/2013

BUENA, N.J., Sept. 18, 2013 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its fourth abbreviated new drug application (ANDA) in 2013 to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions to twelve.

(Logo: http://photos.prnewswire.com/prnh/20130827/MM70487LOGO)

Jason Grenfell-Gardner, President and CEO of the Company, commented, "Today's submission brings our total number of abbreviated new drug applications on file with the FDA to twelve.  Our research and development team remains on track to deliver on our expectation to file at least six ANDAs in 2013.  The foundation of our strategic plan to create value and accelerate our future growth at IGI centers on our ANDA pipeline, and our team at IGI continues to deliver on our plan.  Our continued successful research and development efforts, supported by the expansion of our contract manufacturing and formulation services business, should enable IGI to achieve the financial goals we established at the beginning of 2013, to double 2012 total revenue and achieve profitability in 2013."

About IGI Laboratories, Inc.
IGI Laboratories is a generic topical pharmaceutical company.  We develop and manufacture topical formulations for the pharmaceutical, OTC, and cosmetic markets. Our mission is to be a leading player in the generic topical prescription drug market.

Forward-Looking Statements
This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as "plan," "believe," "continue", "should" or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to complete successfully future product acquisitions.  These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.'s most recent Annual Report on Form 10-K,  Quarterly Reports on Form 10-Q and other periodic reports we file with the Securities and Exchange Commission.  IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.


'/>"/>
SOURCE IGI Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. MO BIO Laboratories, Inc. launches a new kit for isolation of viral nucleic acids from environmental samples
2. Global Vascular Stents Market 2012-2016 Report with Abbott Laboratories, Medtronic Inc. and Boston Scientific Corp. Dominating
3. Charleston Laboratories, Inc. Announces Successful Completion of Pre-IND Meeting on New Migraine Treatment CL-H1T
4. Clontech Laboratories, Inc. Partners With Rubicon Genomics To Increase Speed And Efficiency Of Sample Preparation For RNA Sequencing
5. Besins Healthcare, Shin Nippon Biomedical Laboratories, Ltd Announce Delivery Technology Licensing Agreement for Intranasal Progesterone
6. FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment
7. Antigen Laboratories, Inc. to be Acquired by Ares Life Sciences
8. Positive Data, Pipeline Improvements & Market Expansion - Research Report on Abbott Laboratories, Stryker Corporation, St. Jude Medical, Cardiovascular Systems and MAKO Surgical
9. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
10. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
11. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... Sept. 6, 2017  Medical professionals are ... skills while treating their patients. Medical simulations ... without involving patients. Simulation provides a safe ... carry out procedures, refine techniques and build ... of new technology, such as augmented reality, ...
(Date:9/5/2017)... KEYSTONE, Colo. , Sept. 5, 2017 ... their XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party ... update existing CT scanners and allows compliance with current ... The Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically ... notifications and alerts of potential radiation doses over a ...
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... September 19, 2017 , ... When it comes to household ... deserve clear instructions on how to keep babies and toddlers safe, and there's no ... Safety Month. , Great Time to Check Labels, Brands that sell all kinds of ...
(Date:9/19/2017)... ... September 19, 2017 , ... With Netmail ... contractors in the United States, can easily manage all of their data, apply ... on premise platforms simultaneously. “As a construction company,” says Ryan Sinnwell, the Infrastructure ...
(Date:9/18/2017)... (PRWEB) , ... September 18, 2017 , ... A September ... University in Belfast indicating that aspirin, one of the world’s most common and least ... teeth. Los Angeles area dentist Dr. Farzad Feiz of California Dental Group and Calabasas ...
(Date:9/18/2017)... ... ... Allegheny Health Network’s (AHN) string of standout showings at the Pittsburgh Business Times’ ... honors than any health care provider in the region at the annual event. ... William Penn Hotel in downtown Pittsburgh included:, , George J. ...
(Date:9/18/2017)... ... September 18, 2017 , ... Healthpointe is proud ... Southern California. Patients with chronic back pain, neck pain, muscle spasms, and/or tenderness ... department. , Each of Healthpointe’s eleven offices now has a licensed chiropractor that ...
Breaking Medicine News(10 mins):